v3.21.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Revenue:    
Grant and contract revenue $ 2,947,969 $ 3,049,104
Operating expenses:    
Research and development 12,938,895 13,013,604
General and administrative 14,934,436 9,431,015
Goodwill impairment loss 0 737,000
Change in fair value of contingent consideration 1,199,000 613,290
Total operating expenses 29,072,331 23,794,909
Loss from operations (26,124,362) (20,745,805)
Change in fair value of warrant liability (1,012,167)  
Investor relations expense (66,767)  
Interest income 566,718 431,824
Other income (expense), net 255,189 (25,557)
Total non-operating (loss) income (257,027) 406,267
Net loss before income taxes (26,381,389) (20,339,538)
Income tax expense   (45,178)
Net loss (26,381,389) (20,384,716)
Net loss - non-controlling interest (331,652) (367,148)
Net loss attributable to Heat Biologics, Inc. $ (26,049,737) $ (20,017,568)
Net loss per share applicable to Heat Biologics, Inc - basic and diluted $ (1.63) $ (4.21)
Weighted-average number of common shares used in net loss per share attributable to Heat Biologics, Inc.-basic and diluted 15,982,568 4,754,542
Comprehensive loss    
Net loss $ (26,381,389) $ (20,384,716)
Unrealized (loss) gain on foreign currency translation (154,806) 8,654
Total comprehensive loss (26,536,195) (20,376,062)
Comprehensive loss attributable to non-controlling interest (331,652) (367,148)
Comprehensive loss - Heat Biologics, Inc. $ (26,204,543) $ (20,008,914)

Source